Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,070,298 shares of AKBA stock, worth $18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,070,298
Previous 9,276,263
8.56%
Holding current value
$18 Million
Previous $9.46 Million
40.49%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AKBA
# of Institutions
121Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$20.8 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.3 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.51 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.65 Million0.01% of portfolio
-
State Street Corp Boston, MA3.43MShares$6.14 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $329M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...